Giuseppe Curigliano, MD, PhD, University of Milano, Milan, Italy, discusses low HER2 expression metastatic breast cancer and its treatment with antibody-drug conjugates. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).